# US 8,771,757 B2 · Method for the preparation of a silicic acid comprising extrudate, said extrudate, its use and a pharmaceutical composition comprising the said extrudate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,771,757 B2
- Document ID: US8771757B2
- Status: Granted
- Kind: B2
- Application number: 10/524,189
- Filed: 2003-08-12
- Published: 2006-05-11
- Granted: 2014-07-08
- Earliest claimed: 2002-08-12
- Assignees: Biominerals N.V.
- Applicants: Dirk André Richard Vanden Berghe
- Inventors: Dirk André Richard Vanden Berghe
- Web page: https://patentgrep.com/patent/US8771757B2

## CPC

- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A23K 20/28: Silicates, e.g. perlites, zeolites or bentonites
- A23K 40/20: by moulding, e.g. making cakes or briquettes
- A23K 40/25: by extrusion
- A23L 29/015: {Inorganic compounds}
- A23P 10/25: Agglomeration or granulation by extrusion or by pressing, e.g. through small holes, through sieves or between surfaces
- A23P 10/30: Encapsulation of particles, e.g. foodstuff additives
- A61K 8/25: Silicon; Compounds thereof
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61Q 19/08: Anti-ageing preparations
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K 2800/92: Oral administration
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23K: FODDER
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A23P: SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The invention relates to a method for the preparation of a silicic acid comprising extrudate, comprising the steps of: i) forming of stabilized silicic acid, by hydrolysing a silicon compound into orthosilicic acid and/or oligomers thereof in the presence of a stabilizing agent, which is a quaternary ammonium compound, or an amino-acid, or an amino acid source or combinations thereof; ii) mixing of the stabilized silicic acid with a carrier in an amount upto the loading capacity of the carrier for silicic acid; and iii) extruding the resulting mixture thereby forming the extrudate, to extrudates obtainable with the method, to an extrudate for use in the production of animal feed, feed supplement, human food and/or food supplement and of a pharmaceutical or cosmetic preparation, and for the treatment of infections, nails, hair, skin, teeth, collagen, connective tissue, bones, osteopenia, cell generation and degenerative (ageing) processes, and to a pharmaceutical composition comprising an extrudate.

## Claims

### Claim 1

A method for the preparation of a bioavailable silicic acid including extrudate, comprising:
forming stabilized silicic acid, by hydrolysing a silicon compound into orthosilicic acid and/or oligomers thereof in the presence of a stabilizing agent, which is a quaternary ammonium compound consisting essentially of choline;
mixing the stabilized silicic acid with a carrier in an amount up to the loading capacity of the carrier for silicic acid; and
extruding the resulting mixture thereby forming the extrudate that provides the stabilized silicic acid in a bioavailable solid form.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the quaternary ammonium compound is choline chloride.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the stabilized silicic acid comprises a silicon content of 2.5-3.5% by volume, a choline content of 65-75% by weight and a water content of 15-25% by weight.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the carrier is mixed with the stabilised silicic acid in a ratio of 65-50% and 35-50% respectively.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the carrier is cellulose or a derivatives thereof such as microcrystalline cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, and cellulose gum and/or other carriers or combinations selected from sugars such as lactose, pectines and alginates, poly- and oligosaccharides such as malto-dextrine, glucans and derivatives thereof, starch and derivatives thereof, and natural and semi-synthetic fibers, protein and protein hydrolysates.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the carrier is microcrystalline cellulose and the loading capacity for stabilised silicic acid <50%.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the extrudate is spheronized into particles.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the particles are dried and have a particle size between about 800 to about 1200 μm.